NIKKEI 225
27,368.58 -64.82 (-0.24%) HANG SENG
21,805.76 -263.97 (-1.20%) CRUDE OIL
77.57 -0.33 (-0.42%) GOLD FUTURES
1,935.10 -4.10 (-0.21%) DOW
33,717.09 -260.99 (-0.77%) BTC-GBP
18,528.24 -757.44 (-3.93%)
CureVac N.V. (CVAC)
After hours:
- EQS Group
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)
Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i
- Motley Fool
Why CureVac's Shares Jumped on Tuesday
Shares of CureVac (NASDAQ: CVAC) rose as much as 19.1% on Tuesday. Despite the rise, CureVac is down more than 59% over the past year, though it is now up more than 61% over the past three months. Investors continued to flock to the healthcare stock after the biotech announced late Friday that several of its messenger RNA vaccines were doing well in early trials.
- EQS Group
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
Issuer: CureVac / Key word(s): Personnel09.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new cla
